Abstract:
:Funded immunization programs are best able to achieve high participation rates, optimal protection of the target population, and indirect protection of others. However, in many countries public funding of approved vaccines can be substantially delayed, limited to a portion of the at-risk population or denied altogether. In these situations, unfunded vaccines are often inaccessible to individuals at risk, allowing potentially avoidable morbidity and mortality to continue to occur. We contend that private access to approved but unfunded vaccines should be reconsidered and encouraged, with recognition that individuals have a prerogative to take advantage of a vaccine of potential benefit to them whether it is publicly funded or not. Moreover, numbers of "approved but unfunded" vaccines are likely to grow because governments will not be able to fund all future vaccines of potential benefit to some citizens. New strategies are needed to better use unfunded vaccines even though the net benefits will fall short of those of funded programs. Canada, after recent delays funding several new vaccine programs, has developed means to encourage private vaccine use. Physicians are required to inform relevant patients about risks and benefits of all recommended vaccines, publicly funded or not. Likewise, some provincial public health departments now recommend and promote both funded and unfunded vaccines. Pharmacists are key players in making unfunded vaccines locally available. Professional organizations are contributing to public and provider education about unfunded vaccines (e.g. herpes zoster, not funded in any province). Vaccine companies are gaining expertise with direct-to-consumer advertising. However, major challenges remain, such as making unfunded vaccines more available to low-income families and overcoming public expectations that all vaccines will be provided cost-free, when many other recommended personal preventive measures are user-pay. The greatest need is to change the widespread perception that approved vaccines should be publicly funded or ignored.
journal_name
Vaccinejournal_title
Vaccineauthors
Scheifele DW,Ward BJ,Halperin SA,McNeil SA,Crowcroft NS,Bjornson Gdoi
10.1016/j.vaccine.2013.12.027subject
Has Abstractpub_date
2014-02-07 00:00:00pages
766-70issue
7eissn
0264-410Xissn
1873-2518pii
S0264-410X(13)01758-1journal_volume
32pub_type
杂志文章,评审相关文献
VACCINE文献大全abstract::The immunopotentiating activities of colloidal iron hydroxide, a novel, experimental mineral adjuvant, and of aluminium hydroxide. the licensed adjuvant for human vaccines, were compared. Our studies revealed that colloidal iron hydroxide and aluminium hydroxide behaved comparably with respect to supporting induction ...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/s0264-410x(98)00201-1
更新日期:1999-03-05 00:00:00
abstract::In order to evaluate the long-term immunity 2 and 3 years after booster vaccination against tick-borne encephalitis (TBE) following time intervals 3 years and longer since last TBE immunization, 195 (mean age 50.5+/-15.1 years) and 240 subjects (mean age 47.0+/-15.4 years), respectively, who had received a single boos...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2007.01.116
更新日期:2007-06-28 00:00:00
abstract::Carbopol is a polyanionic carbomer gel used in man for a variety of topical applications and drug delivery purposes. Here we show that subcutaneous administration of carbopol with glycoprotein antigens elicits unusually strong specific adaptive immune responses in mice. Recombinant soluble HIV-1 envelope glycoprotein ...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2010.01.046
更新日期:2010-03-16 00:00:00
abstract::Intranasal (i.n.) immunization is an effective regimen for the prophylaxis of respiratory diseases in early life. The aim of this study was to assess the need for nasal-associated lymphoid tissue (NALT) and cervical lymph nodes (CLN) in induction of protective immunity following mucosal vaccination of infant mice. We ...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2008.01.027
更新日期:2008-03-17 00:00:00
abstract::The new intradermal DNA delivery technique, termed DNA tattooing might overcome the discrepancy between the encouraging immunogenicity results obtained with DNA vaccines in murine studies and the poor results obtained in non-human primates and humans, the so called "simian barrier". Here, we demonstrate a 10- to 100-f...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2008.03.091
更新日期:2008-06-19 00:00:00
abstract:OBJECTIVE:In response to the emergence of influenza viruses with pandemic potential, we evaluated a swine-origin influenza A/H3N2 variant (H3N2v) vaccine in children. STUDY DESIGN:This multicenter phase II open-label study assessed the safety and immunogenicity of two doses, 21 days apart, of investigational unadjuvan...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2019.07.085
更新日期:2019-08-23 00:00:00
abstract:BACKGROUND:The Post-Licensure Rapid Immunization Safety Monitoring (PRISM) program is the immunization safety monitoring component of FDA's Mini-Sentinel project, a program to actively monitor the safety of medical products using electronic health information. FDA sought to assess the surveillance capabilities of this ...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2013.04.088
更新日期:2013-12-30 00:00:00
abstract::The presence of resident Langerhans cells (LCs) in the epidermis makes the skin an attractive target for DNA vaccination. However, reliable animal models for cutaneous vaccination studies are limited. We demonstrate an ex vivo human skin model for cutaneous DNA vaccination which can potentially bridge the gap between ...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2009.07.088
更新日期:2009-10-09 00:00:00
abstract:INTRODUCTION:During the 2018-2019 influenza season, vaccination coverage among U.S. children was 62.6%. The purpose of this study was to estimate the prevalence of influenza vaccinations among pediatric patients seen in U.S. health centers, and to explore potential disparities in vaccination coverage among subpopulatio...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2020.07.021
更新日期:2020-09-03 00:00:00
abstract::Monoclonal antibodies (MoAbs) reactive with the authentic Orientia tsutsugamushi 56-kDa protein were generated. MoAb FS10 and FS15 showed in vitro, as well as, in vivo neutralizing activity upon O. tsutsugamushi infection. Deletion mutants of the gene for 56-kDa protein of O. tsutsugamushi Boryong were expressed to ma...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/s0264-410x(00)00167-5
更新日期:2000-08-15 00:00:00
abstract::Confidence in vaccine safety is critical to national immunization strategies and to global public health. To meet the Millenium Development Goals, and buoyed by the success of new vaccines produced in developing countries, the World Health Organization has been developing a strategy to establish a global system for ef...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2012.05.045
更新日期:2012-07-13 00:00:00
abstract::Human respiratory syncytial virus (RSV) is a leading cause of severe respiratory disease and hospitalizations in infants and young children. It also causes significant morbidity and mortality in elderly and immune compromised individuals. No licensed vaccine currently exists. Parainfluenza virus 5 (PIV5) is a paramyxo...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2014.03.049
更新日期:2014-05-23 00:00:00
abstract::We compared the effects of yeast-treated human dendritic cells (DCs) with CD40L-matured human DCs for the induction of effector cells and the number and functionality of CD4(+)CD25(+)CD127(-)FoxP3(+) regulatory T cells (Tregs). DCs were treated with yeast or CD40L and cocultured with isolated autologous CD4(+) T cells...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2011.04.101
更新日期:2011-07-12 00:00:00
abstract::Respiratory syncytial virus (RSV) is a major respiratory pathogen responsible for severe pulmonary disease. We have developed a parenterally administered vaccine, BBG2Na, which is currently in a phase III clinical trial. BBG2Na comprises residues 130--230 of RSV-A G protein (G2Na) fused to the BB carrier protein. In t...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/s0264-410x(01)00105-0
更新日期:2001-07-16 00:00:00
abstract::Systemic (spleen cell (SPLC), serum antibodies) and intestinal mucosal (Peyer's patch cells (PPC), lamina propria lymphocytes (LPLs), coproantibodies) immune responses were compared in mice immunized with varying doses (144, 72, 36, 18 ELISA units [EU]) of HAVRIX, an alum-adsorbed killed hepatitis A virus (HAV) vaccin...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/s0264-410x(02)00699-0
更新日期:2003-03-28 00:00:00
abstract::EBA-175 protein is used as ligand in Plasmodium falciparum binding to erythrocytes. Evidence shows that conserved peptide 1815 from this protein having high red blood cell binding ability plays an important role in the invasion process. This peptide is neither immunogenic nor protective. Residues were substituted by a...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2004.08.052
更新日期:2005-02-18 00:00:00
abstract::The 2-1-1 rabies postexposure treatment schedule is an abbreviated regimen in which a tissue culture rabies vaccine is administered intramuscularly at two sites on day 0, and at one site on days 7 and 21. Compared to the standard five-dose intramuscular regimen, the 2-1-1 schedule reduces the number of clinic visits f...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/0264-410x(91)90244-z
更新日期:1991-08-01 00:00:00
abstract:BACKGROUND:Germany introduced routine varicella (V) vaccination in 2004. Due to a slightly increased risk of febrile convulsions after first-dose application of combined measles-mumps-rubella-varicella (MMRV) vaccine separate first-dose vaccinations with MMR and monovalent V vaccine were recommended in September 2011. ...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2013.12.065
更新日期:2014-02-12 00:00:00
abstract::Human papillomaviruses (HPV), particularly HPV16, is considered a necessary cause of cervical and oral cancer. Thus, the development of a therapeutic vaccine against HPV is important for the control of cervical cancer. However, therapeutic vaccination has been limited by inadequate antigen-specific immune responses. H...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2007.12.034
更新日期:2008-03-04 00:00:00
abstract:BACKGROUND:A randomized trial demonstrated that a high-dose inactivated influenza vaccine (IIV-HD) was 24.2% more efficacious than a standard-dose vaccine (IIV-SD) against laboratory-confirmed influenza illness in adults ≥65 years. To evaluate the consistency of IIV-HD benefits, supplemental analyses explored efficacy ...
journal_title:Vaccine
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1016/j.vaccine.2015.07.003
更新日期:2015-08-26 00:00:00
abstract::Cellular as well as humoral immune reactivity were studied in healthy young (< 30 years; n = 12) and older (> 65 years; n = 12) individuals before as well as 1 month after immunization with a trivalent whole virus influenza vaccine. Before vaccination, peripheral blood mononuclear cell proliferation in response to in ...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/s0264-410x(97)88329-6
更新日期:1998-01-01 00:00:00
abstract::An inactivated hepatitis A vaccine was given to 104 seronegative volunteers aged between 19 and 60 years according to two schedules: 0, 1 and 2 months or 0, 1 and 6 months. The vaccine was well tolerated and 97 and 100% of vaccinees developed a serum antibody response following a single and two doses of vaccine respec...
journal_title:Vaccine
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1016/0264-410x(92)90563-y
更新日期:1992-01-01 00:00:00
abstract::The availability of an inactivated hepatitis A virus (HAV) vaccine, and the development of live attenuated virus vaccines against hepatitis represent great advances in the effort to control an important cause of viral hepatitis. There are a number of ways hepatitis A vaccines could be used, depending on the epidemiolo...
journal_title:Vaccine
pub_type: 杂志文章,评审
doi:10.1016/0264-410x(92)90555-x
更新日期:1992-01-01 00:00:00
abstract::The avian paramyxoviruses (APMVs) belong to the genus Avulavirus of family Paramyxoviridae. The APMVs are classified into nine serotypes on the basis of hemagglutination inhibition (HI) and neuraminidase inhibition (NI) assays, although some serologic cross-reaction exists. Newcastle disease virus (NDV), which constit...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2011.12.090
更新日期:2012-03-09 00:00:00
abstract:INTRODUCTION:Widespread introduction of pneumococcal conjugated vaccines (PCVs) impacted on invasive pneumococcal disease (IPD). However, IPD reduction may not be similar in all outcomes within IPD. We assessed PCV7/PCV13 impact on pneumococcal meningitis, bacteremic pneumonia (BP) and other (non-meningitis, non-pneumo...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2017.05.059
更新日期:2018-08-28 00:00:00
abstract::We have recently developed a transmissible vaccine to immunize rabbits against myxomatosis and rabbit haemorrhagic disease based on a recombinant myxoma virus (MV) expressing the rabbit haemorrhagic disease virus (RHDV) capsid protein [Bárcena et al. Horizontal transmissible protection against myxomatosis and rabbit h...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/s0264-410x(00)00183-3
更新日期:2000-09-15 00:00:00
abstract::After introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in the infant national immunization program (NIP) in the Netherlands in 2006, Streptococcus pneumoniae strains of the non-vaccine serotype 19A emerged and became the dominant serotype in carriage in children and their parents. Similar patterns we...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2015.11.060
更新日期:2016-01-20 00:00:00
abstract::A HIV-1 tier system has been developed to categorize the various subtype viruses based on their sensitivity to vaccine-induced neutralizing antibodies (NAbs): tier 1 with greatest sensitivity, tier 2 being moderately sensitive, and tier 3 being the least sensitive to NAbs (Mascola et al., J Virol 2005; 79:10103-7). He...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2013.05.024
更新日期:2014-02-03 00:00:00
abstract::Influenza vaccines minimize the risk of influenza-related morbidity, complication, and death in elderly people. Although evaluating vaccine effectiveness (VE) is important for promoting immunization programs and coping with influenza epidemics, it is difficult to evaluate its effectiveness in Japan, where no framework...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2017.07.002
更新日期:2017-08-24 00:00:00
abstract::Aluminium-containing adjuvants are often used to enhance the potency of vaccines. In the present work we studied whether adsorption of diphtheria toxoid to colloidal aluminium hydroxide induces conformational changes of the antigen. Diphtheria toxoid has a high affinity for the aluminium hydroxide particles based on a...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2012.09.020
更新日期:2012-11-06 00:00:00